by Dr. C.H. Weaver M.D. 3/2021
In July 2020 the United States Food and Drug Administration (FDA) granted fast track designation to enzastaurin for the treatment of patients with newly diagnosed glioblastoma.
Enzastaurin (DB102) is an orally available, investigational first-in-class small molecule serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways. Data suggest the addition of high dose enzastaurin to temozolomide may improve outcomes among patients with glioblastoma who have the DGM1 biomarker, regardless of MGMT methylation status. A randomized phase 3 trial of enzastaurin with temozolomide during and following radiotherapy among patients with previously untreated glioblastoma has been launched in March 2021.
Understanding DNA Damage Response or DDR and Cancer Treatment
What is DNA Damage Response or DDR?
Other Research Updates
- A newly opened clinical trial at City of Hope will evaluate chlorotoxin-directed chimeric antigen receptor T cells for treatment of brain tumors. Read more.
- The FDA granted fast track designation to TVI-Brain-1 (TVAX Biomedical), an adoptive T cell therapy for the treatment of glioblastoma multiforme. Read more.
- Continued ofranergene obadenovec (VB-111) monotherapy priming after progression with bevacizumab (Avastin) combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study. Read more.
- Maximal resection of the contrast-enhanced tumor appeared associated with longer OS among all subgroups of patients with glioblastoma. Read more.
- Whats being done with CAR T and Immunotherapy? Read more.